{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:31:11Z","timestamp":1768217471369,"version":"3.49.0"},"reference-count":28,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["HL006007"],"award-info":[{"award-number":["HL006007"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Transplant Infectious Dis"],"published-print":{"date-parts":[[2025,11]]},"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Sickle cell disease (SCD) can be cured by hematopoietic cell transplantation (HCT), but patients face increased risk of hepatitis B virus (HBV) reactivation due to immunosuppression. Understanding hepatitis B surface antibody (anti\u2010HBs) kinetics is essential for optimizing HBV revaccination and posttransplant care.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This post hoc analysis examined HBV immunity, reactivation, and revaccination response in 71 SCD patients who underwent HCT at the National Heart, Lung, and Blood Institute (2008\u20132021) using alemtuzumab and low\u2010dose total body irradiation.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n At baseline, 55% showed HBV immunity (anti\u2010HBs \u2265 12 mIU\/mL). Most patients responded to revaccination regardless of baseline immunity. Post\u2010HCT revaccination was given to 93%, with 89% completing full series (Heplisav\u2010B or Engerix\u2010B). Vaccinated patients had a 67.5% chance of increased anti\u2010HBs titers between Years 1 and 2, though no significant difference was seen compared to unvaccinated patients (\n p<\/jats:italic>\n = 0.12). No HBV reactivation occurred; two patients with baseline HBcAb and HBsAg positivity showed decreasing HBV DNA levels.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n Results indicate that HBV immunity can decline post\u2010HCT, but most patients remain immune, and revaccination is effective. However, some non\u2010responders\u2014especially those treated with IVIG, rituximab, or prolonged immunosuppression\u2014need further study. Prospective research is needed to optimize revaccination timing and immune monitoring in this high\u2010risk group.\n \n \n image<\/jats:alt-text>\n <\/jats:graphic>\n <\/jats:boxed-text>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/tid.70097","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T14:36:12Z","timestamp":1757601372000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease"],"prefix":"10.1111","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1074-8480","authenticated-orcid":false,"given":"Henna","family":"Butt","sequence":"first","affiliation":[{"name":"Cellular and Molecular Therapeutics Branch National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda Maryland USA"},{"name":"Center for Cancer and Blood Disorders Children's National Hospital Washington, DC USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Jeffries","sequence":"additional","affiliation":[{"name":"Office of Biostatistics Research National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Triscia","family":"Martin","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Therapeutics Branch National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda Maryland USA"},{"name":"Clinical Monitoring Research Program Directorate Frederick National Laboratory for Cancer Research Frederick Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"De Giorgi","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine Clinical Center National Institutes of Health Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Zamora","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine Clinical Center National Institutes of Health Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Tisdale","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Therapeutics Branch National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3706-6615","authenticated-orcid":false,"given":"Matthew M.","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Therapeutics Branch National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda Maryland USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00118-7"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1510865"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61029-X"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.13.1645"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2014.08.014"},{"key":"e_1_2_7_7_1","unstructured":"World Health Organization \u201cHepatitis B \u201d2024 https:\/\/www.who.int\/news\u2010room\/fact\u2010sheets\/detail\/hepatitis\u2010b."},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17991"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1586\/eri.11.105"},{"issue":"3","key":"e_1_2_7_10_1","article-title":"Hepatitis B and C in Hematopoietic Stem Cell Transplant","volume":"1","author":"Locasciulli A.","year":"2009","journal-title":"Mediterranean Journal of Hematology and Infectious Diseases"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.04.004"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04206-z"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1118"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000151661.52601.FB"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703826"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13044"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13243"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.05.001"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-023-04685-8"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236140"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14024"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000546"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13563"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000128"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126705"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-017-3868-0"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198909143211103"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-3-356"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.01.007"}],"container-title":["Transplant Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.70097","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/tid.70097","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/tid.70097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:33:55Z","timestamp":1768206835000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/tid.70097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1111\/tid.70097"],"URL":"https:\/\/doi.org\/10.1111\/tid.70097","archive":["Portico"],"relation":{},"ISSN":["1398-2273","1399-3062"],"issn-type":[{"value":"1398-2273","type":"print"},{"value":"1399-3062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"2025-09-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70097"}}